128 related articles for article (PubMed ID: 29040185)
1. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy.
Kiyotoki T; Nakamura K; Haraga J; Omichi C; Ida N; Saijo M; Nishida T; Kusumoto T; Masuyama H
Int J Gynecol Cancer; 2018 Jan; 28(1):168-175. PubMed ID: 29040185
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
Matsuoka H; Nakamura K; Matsubara Y; Ida N; Nishida T; Ogawa C; Katsi K; Kanazawa S; Masuyama H
Anticancer Res; 2019 Feb; 39(2):933-939. PubMed ID: 30711978
[TBL] [Abstract][Full Text] [Related]
3. The Glasgow Prognostic Score Determined During Concurrent Chemoradiotherapy Is an Independent Predictor of Survival for Cervical Cancer.
Nishida T; Nakamura K; Haraga J; Ogawa C; Kusumoto T; Seki N; Masuyama H; Katayama N; Kanazawa S; Hiramatsu Y
Int J Gynecol Cancer; 2015 Sep; 25(7):1306-14. PubMed ID: 26067860
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
6. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
[TBL] [Abstract][Full Text] [Related]
7. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.
Mabuchi S; Ugaki H; Isohashi F; Yoshioka Y; Temma K; Yada-Hashimoto N; Takeda T; Yamamoto T; Yoshino K; Nakajima R; Kuragaki C; Morishige K; Enomoto T; Inoue T; Kimura T
Gynecol Obstet Invest; 2010; 69(4):224-232. PubMed ID: 20068328
[TBL] [Abstract][Full Text] [Related]
8. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
9. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
10. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
12. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
13. Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy.
Kise S; Arakaki Y; Kudaka W; Ariga T; Kinjo N; Kohatu H; Aoki Y
Anticancer Res; 2022 Oct; 42(10):4887-4893. PubMed ID: 36191992
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
Cho O; Chun M; Chang SJ; Oh YT; Noh OK
Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
[TBL] [Abstract][Full Text] [Related]
16. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
[TBL] [Abstract][Full Text] [Related]
17. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.
Yoon HI; Cha J; Keum KC; Lee HY; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
Radiat Oncol; 2015 Jan; 10():18. PubMed ID: 25582425
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
Wu CE; Lin YC; Hong JH; Chuang CK; Pang ST; Liaw CC
Anticancer Res; 2013 Jun; 33(6):2605-10. PubMed ID: 23749915
[TBL] [Abstract][Full Text] [Related]
20. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Lee YY; Park W; Huh SJ; Yoon A; Park JY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Anticancer Res; 2013 Oct; 33(10):4675-81. PubMed ID: 24123048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
